GE HealthCare Technologies Inc. (NASDAQ:GEHC) Given Average Rating of “Moderate Buy” by Analysts

GE HealthCare Technologies Inc. (NASDAQ:GEHC) has earned a consensus rating of “Moderate Buy” from the fifteen research firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $96.00.

A number of equities analysts have recently weighed in on GEHC shares. Wells Fargo & Company upped their target price on GE HealthCare Technologies from $95.00 to $96.00 and gave the company an “overweight” rating in a report on Thursday, October 31st. Jefferies Financial Group raised shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and lifted their target price for the company from $95.00 to $103.00 in a research note on Wednesday, January 8th.

GE HealthCare Technologies Price Performance

Shares of NASDAQ GEHC opened at $87.51 on Tuesday. The firm has a 50-day moving average of $82.97 and a two-hundred day moving average of $85.09. The company has a market capitalization of $39.98 billion, a price-to-earnings ratio of 24.04, a PEG ratio of 2.92 and a beta of 1.14. The company has a current ratio of 1.23, a quick ratio of 0.98 and a debt-to-equity ratio of 1.12. GE HealthCare Technologies has a twelve month low of $72.61 and a twelve month high of $94.55.

GE HealthCare Technologies Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Tuesday, January 14th will be issued a dividend of $0.035 per share. The ex-dividend date is Tuesday, January 14th. This is a boost from GE HealthCare Technologies’s previous quarterly dividend of $0.03. This represents a $0.14 annualized dividend and a dividend yield of 0.16%. GE HealthCare Technologies’s dividend payout ratio (DPR) is currently 3.85%.

Insider Transactions at GE HealthCare Technologies

In related news, CEO Roland Rott sold 3,577 shares of the company’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $86.48, for a total transaction of $309,338.96. Following the completion of the sale, the chief executive officer now directly owns 24,298 shares in the company, valued at $2,101,291.04. This represents a 12.83 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.27% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. LGT Financial Advisors LLC boosted its position in GE HealthCare Technologies by 1,673.3% during the third quarter. LGT Financial Advisors LLC now owns 266 shares of the company’s stock valued at $25,000 after acquiring an additional 251 shares during the last quarter. Ashton Thomas Securities LLC bought a new position in shares of GE HealthCare Technologies during the 3rd quarter worth approximately $26,000. Capital Performance Advisors LLP bought a new stake in shares of GE HealthCare Technologies in the 3rd quarter valued at $26,000. Darwin Wealth Management LLC acquired a new stake in GE HealthCare Technologies in the third quarter worth $31,000. Finally, Continuum Advisory LLC raised its holdings in shares of GE HealthCare Technologies by 101.8% during the third quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock valued at $31,000 after purchasing an additional 168 shares during the period. Institutional investors own 82.06% of the company’s stock.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.